EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial

Jiasheng Ma iD, Miaoyu Zeng, Chi-Jen Hsu iD, Dandan Li, Mei Na Fok, Yan Jiang, Qiaoqiao Li, Jie Ma, Jiaze Zhou, Brian Shiian Chen iD, Fengju Li

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.15319 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Jiasheng Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Puyang Oilfield General Hospital, Puyang, China. Hauptthemen laut MEDLINE: Methotrexate, Hydroxychloroquine, Arthritis, Rheumatoid, Drug Therapy, Combination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the efficacy and safety of combination therapy with methotrexate (MTX) plus hydroxychloroquine (HCQ) vs. MTX monotherapy in patients with rheumatoid arthritis (RA).

Methods

Sixty patients without prior RA treatments were randomly allocated in a 1:1 ratio to two groups: one receiving MTX plus HCQ, and the other receiving MTX monotherapy. We conducted a comparative analysis before and after the 12‐week trial, evaluating the visual analogue scale (VAS), the disease activity score in 28 joints (DAS), serum inflammatory factor (including serum C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin 6 (IL‐6), tumor necrosis factor‐alpha (TNF‐α), as well as the outcome of the World Health Organization Quality of Life Brief Version questionnaire (WHOQOL‐BREF) and the treatment‐emergent adverse events (TEAEs) for all the participants in the study.

Results

At the 12th week of the trial, a more remarkable decrease in pain score (VAS), disease activity score (DAS), and serum inflammatory factor levels could be noticed in individuals on the combination therapy. The quality of life score was as well found to be higher in the MTX + HCQ group than the MTX monotherapy group. The incidence of adverse reactions in the MTX + HCQ and the MTX monotherapy groups were 10.00% and 6.67%, respectively. However, no statistical significance could be observed ( p > .05).

Conclusion

In our study, both the MTX + HCQ combination therapy and MTX monotherapy demonstrated improvements in symptoms, conditions and quality of life for patients with RA. Notably, the combination therapy could achieve better outcomes across all indices compared to MTX monotherapy, highlighting its potential as the optimal first‐line treatment for RA. © 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateHydroxychloroquineArthritis, RheumatoidDrug Therapy, CombinationAntirheumatic AgentsQuality of LifeHumansFemaleMaleTreatment OutcomeMiddle AgedAdultTime FactorsPain MeasurementBiomarkersAgedInflammation Mediators

Stichwörter der Autor:innen

WHOQOL‐BREFhydroxychloroquinemethotrexaterheumatoid arthritis

Substanzen

MethotrexateHydroxychloroquineAntirheumatic AgentsBiomarkersInflammation Mediators

Autor:innen und Institutionen

  • Department of Rheumatology, Puyang Oilfield General Hospital, Puyang, China.
  • Department of Radiology, Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China.
  • Department of Orthopedics, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China.
  • Centro Hospitalar Conde de São Januário, Macao, SAR China.
  • Department of Immunology & Rheumatology, Puyang Oilfield General Hospital Affiliated with Xinxiang Medical University, Puyang, Henan Province, China.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.

ORCID-Profile: Jiasheng Ma, Chi-Jen Hsu, Brian Shiian Chen

Zitieren

APA

Ma, J., Zeng, M., Hsu, C. J., Li, D., Fok, M. N., Jiang, Y., Li, Q., Ma, J., Zhou, J., Chen, B. S., & Li, F. (2024). Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15319

Vancouver

Ma J, Zeng M, Hsu CJ, Li D, Fok MN, Jiang Y, et al. Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15319

BibTeX
@article{Ma2024,
  author = {Ma, Jiasheng and Zeng, Miaoyu and Hsu, Chi-Jen and Li, Dandan and Fok, Mei Na and Jiang, Yan and Li, Qiaoqiao and Ma, Jie and Zhou, Jiaze and Chen, Brian Shiian and Li, Fengju},
  title = {Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.15319}
}
Kostenlos starten →